Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms, Plasma Cell × Lenalidomide × Clear all

Phase

Phase 2 24 Phase 1 9 Phase 3 6 Phase 1/2 6 Phase NA 1 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 5 Recurrence 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 gamma-Globulins 2 Immunoglobulins, Intravenous 2 Dexamethasone 2 Ciprofloxacin 2 daratumumab 1 Thalidomide 1 MAGEA3 protein, human 1 Lenalidomide 1 Immunoglobulins 1 Clavulanic Acid 1 Calcium Dobesilate 1 Amoxicillin-Potassium Clavulanate Combination 1 Amoxicillin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02419118 2017-11-07

DARA

Vejle Hospital

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡